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Poly (adenosine diphosphate–ribose) polymerase (PARP) is an important regulator of DNA repair and the target of sev-
eral agents in development across tumor types. Geoff Shapiro 
provided a comprehensive review of PARP biology and the 
strong rationale for cancer drug development.
PARP BIOLOGY
DNA repair can occur through several pathways includ-
ing base-excision repair, nuclear-excision repair, mismatch 
repair, homologous repair (HR), nonhomologous end-joining, 
and single-strand annealing.1 PARP plays an important role in 
repairing single-strand breaks through the base-excision repair 
mechanism. PARP inhibitors prevent single-strand break 
repair leading to double-stranded breaks (DSB) and γH2AX 
foci formation.2 DSB repair occurs preferentially through the 
HR pathway.3 This pathway is disrupted in several conditions, 
including ataxia telangiectasia mutated (ATM) deficiency 
(mutations present in 10%–15% of non–small-cell lung can-
cer [NSCLC]), phosphatase and tensin homolog (PTEN) defi-
ciency, Fanconi deficiency, and BRCA1/2 deficiency. DSB 
that are not repaired efficiently lead to cell death. BRCA defi-
cient cells are highly sensitive to single-agent PARP inhibi-
tion. Low BRCA1 expression (mRNA) has been associated 
with improved survival in patients with stage II–IIIA NSCLC 
treated with preoperative cisplatin and gemcitabine.4 PARP 
inhibitors also sensitize cells to the effects of chemotherapy.
PARP INHIBITORS IN CLINICAL DEVELOPMENT 
IN NSCLC
Several inhibitors in clinical development in lung can-
cer were reviewed.
Veliparib
Veliparib (ABT-888; Abbott, Abbott Park, IL) is a 
potent inhibitor of PARP with good oral bioavailability and 
the ability to cross the blood–brain barrier. Veliparib poten-
tiates platinum agents and temozolomide, as well as radia-
tion.5 Veliparib is currently in phase II testing in a multicenter 
first-line randomized trial in unselected patients with NSCLC 
(N = 120). Patients receive carboplatin/paclitaxel with and 
without veliparib. The trial’s primary endpoint is progres-
sion-free survival (PFS). Dr. Shapiro presented a schema for 
a Cancer Therapy Evaluation Program (CTEP)-sponsored 
phase I dose-escalation trial (CTEP 8484) combining velipa-
rib (administered orally daily) with a cyclin-dependent kinase 
inhibitor (SCH727965, days 8 and 22) in patients with BRCA 
proficient cancers.
David Gandara discussed the potential role of PARP 
inhibitors in combination with chemoradiotherapy for locally 
advanced NSCLC. Chemoradiation can prevent HR of DSB 
induced by PARP inhibitors.6 Dr. Gandara presented preclinical 
data showing how veliparib potentiates the antitumor effects 
of platinum and radiation. Data were also presented, which 
demonstrated how squamous tumors express higher levels of 
PARP1, ERCC1, and BRCA 1/2 compared with adenocarci-
nomas. Finally, a schema for a phase I Southwest Oncology 
Group (SWOG) trial (NCI 8811) was presented looking at the 
combination of carboplatin, paclitaxel, veliparib, and radia-
tion in patients with stage III NSCLC. The goal then would 
be to proceed with a randomized placebo-controlled phase II 
trial in 104 patients, where enrollment is stratified by histol-
ogy (squamous versus nonsquamous), performance status, 
and prior weight loss.
Olaparib 
Olaparib (AZD 2281; AstraZeneca, London, England) is 
an oral PARP inhibitor, which has shown potent antitumor activ-
ity in patients with BRCA-mutated breast cancer7 and in ovar-
ian cancer with or without BRCA1 or 2 mutations.8 A pivotal 
phase II dose-escalation trial demonstrated activity in patients 
with refractory and BRCA-mutated ovarian, breast, and pros-
tate cancer. Reversible dose-limiting toxicity included mood 
changes, fatigue, somnolence, and thrombocytopenia. A phase 
II study of olaparib in ovarian cancer demonstrated responses 
in 41% and 24% in patients with and without BRCA1/2 muta-
tions, respectively. Recently, olaparib was studied in a random-
ized phase II trial in patients with platinum-sensitive advanced 
ovarian cancer, who achieved a partial or complete response to 
chemotherapy. Patients (N = 265) were randomized to switch-
maintenance therapy with olaparib 400 mg orally twice daily 
or to placebo. Olaparib improved PFS (median, 8.4 versus 4.8 
months, hazard ratio (HR), 0.35; 95% confidence interval (CI), 
0.25–0.49; p < 0.001). Toxicity included nausea, fatigue, vomit-
ing, and anemia. Giuseppe Giaccone presented results from a 
phase I study at the National Cancer Institute where olaparib 
was combined with cisplatin and gemcitabine in patients with 
refractory solid tumors. This trial was designed to study the 
safety of this combination and find the maximum tolerated dose 
(MTD) of olaparib. This trial also examined chemotherapy’s 
effects, with or without olaparib, on PAR levels in biopsy and 
peripheral blood specimens, pre and post-treatment. Twenty-
three patients were enrolled, eight (35%) of whom had NSCLC.
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Myelosuppression was the primary toxicity and pre-
vented the use of standard doses of chemotherapy with olapa-
rib. The MTD of the combination with olaparib dosed on days 
1 through 4 is olaparib 100 mg orally daily days 1 to 4, cispla-
tin 50 mg/m2 intravenously on day 3, and gemcitabine 400 mg/
m2 intravenously on days 3 and 10. The MTD of the combina-
tion with olaparib dosed on day 1 is olaparib 100 mg twice 
daily on day 1, cisplatin 60 mg/m2 on day 1, and gemcitabine 
500 mg/m2 on days 1 and 8. Olaparib exposure was mod-
estly increased by concomitant gemcitabine, and PAR levels 
dropped with olaparib administration in tumor specimens. 
Levels also declined in peripheral blood mononuclear cells, 
but recovered in some patients by the start of the next cycle. 
Finally, Dr. Giaccone reviewed a multicenter, randomized, 
phase Ib/IIb study still in progress evaluating olaparib and 
gefitinib versus gefitinib alone in patients with EGFR-mutated 
NSCLC being conducted by the Spanish Lung Group.
LY2603618 
LY2603618 (IC-83; Lilly Indianapolis, IN) was pre-
sented within the PARP session, but is not a PARP inhibi-
tor. Rather, this is an inhibitor of the cell-cycle checkpoint 
kinase 1 (chk1), an adenosine triphosphate (ATP)-dependent 
serine-threonine kinase. Chk1 is activated by DSB and is over-
expressed in a number of cancers. Chk1 inhibition prevents 
DNA repair and may potentiate chemotherapy. LY2603618 
has been safely combined with gemcitabine in patients with 
refractory cancers, and was combined with pemetrexed in a 
recently completed trial. Patients with newly diagnosed stage 
IV nonsquamous NSCLC are currently being recruited for a 
single-arm phase II trial of LY2603618, cisplatin, and peme-
trexed, with the primary aim of assessing PFS.
Iniparib 
Iniparib (BSI-201; sanofi-aventis, Paris, France) was 
another agent presented in this session with an antitumor effect 
that seems to be other than PARP inhibition. This agent was 
initially described as a PARP inhibitor and was associated with 
remarkable survival benefits, with no excess toxicity when 
combined with carboplatin and gemcitabine in women with 
metastatic triple-negative breast cancer in a randomized phase 
II study.9 However, the improvement in overall survival could 
not be replicated in a phase III study, and iniparib’s mechanism 
of action was re-explored. Recent data suggested that inipa-
rib may have several antitumor effects including inhibition of 
DNA repair; however, its level of PARP inhibition is consid-
ered modest. Iniparib has been studied in patients with newly 
diagnosed stage IV NSCLC in a randomized phase II study 
presented recently at the 14th World Congress on Lung Cancer 
in Amsterdam.10 One hundred and nineteen patients were ran-
domized to cisplatin and gemcitabine, with or without iniparib. 
The primary endpoint was to assess the objective response rate. 
Investigators found no advantage for the iniparib cohort in terms 
of response; however, the PFS (5.7 versus 4.3 months, HR 0.69) 
and overall survival (11.2 versus 8.5 months, HR 0.75) favored 
iniparib, although not statistically significant. Iniparib is cur-
rently in phase III testing in patients with advanced squamous 
lung cancer. Patients are randomized to carboplatin and gem-
citabine, with or without iniparib. The study’s primary endpoint 
is to assess overall survival.
FUTURE DEVELOPMENT
PARP inhibitors are in active development as single 
agents and in combination with chemotherapy across tumor 
types, including lung cancer. Trials in unselected patients were 
designed with the hypothesis that PARP inhibition benefits all 
patients. A recent positive trial in BRCA-mutated and wild-
type ovarian cancer with maintenance olaparib supports this 
design. However, future development of these agents should 
also include studies focused in patients with tumors already at 
risk for compromised DNA repair. Trials should be designed 
with PARP inhibitors in patients with BRCA1 and 2 meth-
ylated, Excision Repair Cross-Complementing 1 aberrant, 
PTEN-deficient, or ATM-deficient lung cancers. These could 
be single-agent trials, or combination studies with chemother-
apy and/or radiation. Agents such as veliparib, which cross the 
blood–brain barrier, may also play a role in reducing central 
nervous system progression.
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